title: EBV-positive cutaneous B-cell lymphoproliferative disease after imatinib mesylate.
authors: Marcel W
authors: MW
authors: Bekkenk
authors: Maarten H
authors: MH
authors: Vermeer
authors: Chris J L M
authors: CJ
authors: Meijer
authors: Patty M
authors: PM
authors: Jansen
authors: Jaap M
authors: JM
authors: Middeldorp
authors: Servi J C
authors: SJ
authors: Stevens
authors: Rein
authors: R
authors: Willemze
mesh_terms: D000368:Aged; D001402:B-Lymphocytes / Q000473:pathology; D001549:Benzamides; D005260:Female; D004854:Herpesvirus 4, Human; D006801:Humans; D000068877:Imatinib Mesylate; D007165:Immunosuppression Therapy / Q000009:adverse effects; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy; D008232:Lymphoproliferative Disorders / Q000209:etiology* / Q000473:pathology; D016609:Neoplasms, Second Primary / Q000209:etiology* / Q000473:pathology; D010879:Piperazines / Q000009:adverse effects* / Q000627:therapeutic use; D011743:Pyrimidines / Q000009:adverse effects* / Q000627:therapeutic use; D012878:Skin Neoplasms / Q000209:etiology* / Q000473:pathology
chemical_list: D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate